PHIO (Phio Pharmaceuticals) Net Financial Result

PHIO (Phio Pharmaceuticals) - company brandmark

Patent conflicts and tissue regeneration challenges are hindering Phio Pharmaceuticals (PHIO) from reaching profitability. The company's operating profit, as visualized by the GURU.Markets platform, confirms this, stabilizing at -0.01. Future growth relies on the commercialization of the INTASYL system for dermatology, while scaling potential is based on joint research into new immuno-oncology combinations with partners.

Net Income: RXi Pharmaceuticals (PHIO) for 07/04/2022 - 10/30/2026

Financial and market metric breakdowns for phiopharma.com (PHIO)

- stock price and consensus target price:
Price Performance Chart Phio Pharmaceuticals Corp.|PHIO - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization PHIO|PHIO - Total Company Value
- shareholders' equity book value data:
Net Asset Value per Share Phio Pharmaceuticals|PHIO - Company Net Assets|Market Value to Book Value phiopharma.com|PHIO - Aggregate Company Assets
- debt and liquidity details:
Aggregate Debt to Equity Phio Pharmaceuticals|PHIO - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Phio Pharmaceuticals Corp.|PHIO - Company Aggregate Debts|Debts to Book Capitalization PHIO|PHIO - Company Long-Term Debt|Company Short-Term Loans and Borrowings Phio Pharmaceuticals|Quick Liquidity Indicator phiopharma.com
- company profitability and valuation multiples indicators:
PHIO - Net Profit
Fundamental valuation:Phio Pharmaceuticals
Product sample of Phio Pharmaceuticals Corp

This indicator tracks daily net income, allowing for an objective assessment of the business's fundamental stability and the allocation of risks across assets. By analyzing the current profit levels of Phio Pharmaceuticals (PHIO), investors can compare revenue trends against the company's expenditures on early-stage RNA drug development and the minimal costs associated with complying with basic environmental standards for biomaterial disposal.

Main competitors

Tempus AI - Final Profit|QGEN (Qiagen N.V.) - Net Profit|ionispharma.com (IONS) - Net Financial Result|Company Net Income Repligen (RGEN)|RNA - Company Net Income|CRISPR Therapeutics Corp - Net Income|Final Profit WGS|RARE - Company Net Income|Profit After Tax BEAM|SRPT: Net Profit|Twist Bioscience Inc - Final Profit|TXG (10x Genomics Corp) - Net Profit|Net Profit Intellia Corp|Company Net Income Stoke Therapeutics (STOK)|BLFS (biolifesolutions.com) - Final Profit|Company Net Income Wave Life Sciences Ltd. WVE|MAZE - Net Income|Sionna Pharma - Net Profit|PRME - Net Profit|TSHA: Net Profit|Net Income uniqure.com|MGTX (MeiraGTx) - Net Profit|Company Net Income REGENXBIO Inc RGNX|Net Income SLDB (Solid Bio)|Net Profit Ocugen Pharma (OCGN)|Pacific Biosciences - Net Income|Profit After Payment of Taxes BNTC (benitec.com)|Design Therapeutics, Inc. - Net Profit|Net Financial Result Rocket Pharma RCKT|FDMT: Net Profit|Net Income Lexeo Therapeutics, Inc.|KRRO (Korro Bio Inc.) - Net Profit|Net Profit editasmedicine.com|Company Net Income Silence Therapeutics plc (SLN)|Company Net Income PRQR (proqr.com)|Company Net Income Codexis CDXS|Net Financial Result Sangamo BioSciences (SGMO)|NAUT - Company Net Income|Profit After Tax MGX|DTIL: Net Profit|Generation Bio - Final Profit|BOLD (Boundless Bio, Inc) - Net Profit|Exicure Corp (XCUR) - Net Financial Result|Company Net Income Imunon, Inc. (IMNN)|MBIO - Company Net Income|Net Profit RNAZ (TransCode Therapeutics, Inc.)|BNGO: Company Profit|APDN - Company Net Income|BLUE (bluebird bio, Inc) - Company Profit|IPA: Net Profit|omegatherapeutics.com (OMGA) - Net Profit|Company Net Income Singular Genomics|Regulus Therapeutics, Inc. - Profit After Tax|Net Profit SYRS|TBIO (Telesis Bio, Inc) - Final Profit|Net Profit TCON (TRACON Pharmaceuticals)|Net Financial Result unitybiotechnology.com (UBX)